transient receptor potential cation channel subfamily C member 3Genealiases: SCA41 · TRP3
Q-omics provides the consensus-scored TRPC3 profile across patient tissues and cancer cell-line models. TRPC3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TRPC3 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, TRPC3 RNA expression shows 16,132 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and HNSC as cancer lineages where TRPC3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRPC3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRPC3 survival associations across molecular data types. TRPC3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRPC3 RNA expression–survival associations across cancer types. High TRPC3 expression shows unfavorable associations in UVM, LIHC and BLCA, but favorable associations in SKCM, LGG and ACC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TRPC3 RNA expression.
This table summarizes TRPC3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for TRPC3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRPC3 shows lower tumor expression in BLCA, LUSC, LUAD and UCEC and higher tumor expression in HNSC and KICH. The HNSC box plot shows higher TRPC3 RNA expression in tumor versus normal tissue (log2 FC = +0.105, t-test p < 0.001).
This table shows molecular features associated with TRPC3 in patient tissues and cancer cell lines. In patient samples, TRPC3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TRPC3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BLOOD_Lymphoma.
